Ahs Cancer Control Alberta
Clinical trials sponsored by Ahs Cancer Control Alberta, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Home chemo shot study could free myeloma patients from hospital trips Results expected Dec 2026 (estimated)
- Can allergy med stop bone pain in stem cell transplants? Results expected Dec 2026 (estimated)
- New combo therapy aims to ease swallowing in incurable esophageal cancer Results expected Apr 2027 (estimated)
-
Could a lower dose of thyroid hormone be just as effective for advanced cancer?
Disease control Not yet recruitingThis study compares two strategies for using levothyroxine to suppress TSH in patients with advanced thyroid cancer that cannot be fully removed. The standard approach keeps TSH very low (below 0.1), but this can cause side effects. The trial will test if a slightly higher TSH ta…
Phase 2 • Sponsor: AHS Cancer Control Alberta • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Precision radiation boosts cancer fight in Late-Stage esophageal study
Disease control Not yet recruitingThis study looks at adding a precise, high-dose radiation treatment called SBRT to standard chemotherapy and immunotherapy for people with esophageal cancer that has spread to a few other spots in the body. The goal is to see if this combination can help control the cancer longer…
Phase 2 • Sponsor: AHS Cancer Control Alberta • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New Imaging-Guided radiation aims to better control High-Risk prostate cancer
Disease control Not yet recruitingThis study tests whether using PSMA-PET scans to guide radiation therapy can improve cancer control in men with high-risk prostate cancer that hasn't spread to lymph nodes. About 250 participants will receive radiation to the prostate and nearby tissues, with or without whole pel…
Phase 2 • Sponsor: AHS Cancer Control Alberta • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New combo targets hard-to-treat breast cancer in early trial
Disease control Not yet recruitingThis study tests whether adding a targeted drug (olaparib) to a standard chemotherapy (temozolomide) can better control advanced triple-negative breast cancer that has a specific genetic marker (MGMT methylation). About 40 adults with this cancer type will be randomly assigned to…
Phase 2 • Sponsor: AHS Cancer Control Alberta • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Morning infusions may boost lung cancer treatment
Disease control Not yet recruitingThis study looks at whether giving pembrolizumab infusions in the morning improves outcomes for people with metastatic non-small cell lung cancer. 58 participants will be randomly assigned to morning or standard scheduling. The goal is to see if timing affects how long the cancer…
Phase 2 • Sponsor: AHS Cancer Control Alberta • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC